2024澳门原料网站-免费完整资料

Be the most trusted biotech company

2022-05-19

First Patient Dosed for MRCT Phase 3 Studies on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab
2022-05-18

Phase 3 Clinical Study of Henlius Anti-PD-1 mAb, Serplulimab, in Combination with Chemotherapy for Treatment on Patients with Esophageal Squamous Cell Carcinoma Met Primary Endpoints
2022-05-11

Henlius and Eurofarma Entered into a License Agreement for Henlius' 3 Products in Latin America
2022-04-29

IND Application of Phase I Clinical Trial of HANSIZHUANG in combination with Innovative Anti-LAG-3 mAb for the Treatment of Advanced/Metastatic Solid Tumours or Lymphomas Patients was Approved by NMPA
2022-04-28

First Subject Dosed in Phase 3 Clinical Trial of Pertuzumab Biosimilar HLX11
2022-04-20

IND Application for Phase 2 Clinical Trial of Serplulimab in Combination with Bevacizumab and Anti-EGFR mAb for the First-Line Treatment of HCC was Approved by The NMPA
2022-04-19

First Patient in Australia Dosed in a Global Multicentre Phase 3 Clinical Study of Henlius Bevacizumab for treatment of Ophthalmic Diseases
2022-04-11

The NDA of Henlius Novel Anti-PD-1 mAb Serplulimab for the First-Line Treatment of Small Cell Lung Cancer Accepted by NMPA
2022-04-08

First Patient Dosed in a Global Multicentre Phase 3 Clinical Study of Henlius Bevacizumab for treatment of Ophthalmic Diseases in the EU